(NYSE American: VNRX) Is A Top Disruptor In The Field Of Epigenetics (5 Key Potential Catalysts)

The field of epigenetics is rapidly turning what once felt impossible

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (NYSE American: VNRX) Is A Top Disruptor In The Field Of Epigenetics (5 Key Potential Catalysts) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* January 30th Greetings, Friend! The field of epigenetics is rapidly turning what once felt impossible—detecting major health risks through a simple blood test—into reality. VolitionRx Limited (NYSE American: VNRX) is currently at the center of this transformation, developing simple, easy-to-use blood tests that identify specific biomarkers associated with cancer and other diseases. As the medical community shifts toward non-invasive diagnostics, this company's proprietary technology is positioning it to address some of the most significant challenges in modern healthcare. VolitionRx Limited Company Overview VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of nucleosomics. The company specializes in identifying and measuring nucleosomes in the blood, which are structures consisting of DNA wrapped around histone proteins. When cells are damaged or diseased, these nucleosomes are released into the bloodstream with specific epigenetic modifications. By detecting these signatures, VNRX aims to provide clinicians with a "window" into the body’s health without the need for invasive tissue biopsies. Operating primarily through its Nu.Q® platform, the company has developed a suite of assays designed for both human and animal health. The technology is versatile, with applications ranging from cancer screening to the monitoring of acute conditions like sepsis. Recently, the company reached a major commercial milestone by announcing the first sale of its Nu.Q®. Cancer Assays for clinical certification in Europe, marking a transition from research and development toward routine clinical use. Core Thesis: Pioneering Liquid Biopsy Solving the "Needle in a Haystack" Problem One of the primary hurdles in liquid biopsy is the difficulty of detecting rare circulating tumor DNA (ctDNA) amidst a sea of healthy DNA. In December 2025, VNRX announced a technological breakthrough involving its Nu.Q® Capture technology. The company achieved a 180-fold (18,000%) enrichment of tumor-derived DNA. This advancement significantly enhances the sensitivity of sequencing, potentially allowing for the detection of cancer at much earlier stages when treatment is most effective. Strategic Expansion into Acute Care Beyond chronic disease, VNRX is targeting the high-stakes environment of intensive care units. The company's Nu.Q® NETs assay has been included in a major real-world evaluation in France for the early detection of sepsis. Sepsis is a leading cause of hospital mortality, and the ability to quantify Neutrophil Extracellular Traps (NETs) could provide doctors with a critical tool to identify at-risk patients hours or even days earlier than current methods. Robust Intellectual Property and Pipeline The company’s growth is underpinned by an extensive patent portfolio covering its nucleosome detection methods. With 2025 serving as a pivotal year for clinical data, VNRX recently presented two abstracts at the North America Conference on Lung Cancer, further validating the utility of Nu.Q® in hard-to-detect respiratory malignancies. This continuous stream of clinical evidence is vital for securing regulatory approvals and insurance reimbursement. Financial and Operational Strength As of the third quarter 2025, VNRX reported a cash position of approx. $12.3Mn. The company has been disciplined in its capital allocation, focusing on high-value commercial partnerships and streamlining its manufacturing processes. The management team, led by CEO Cameron Reynolds, brings decades of experience in the biotechnology sector, specifically in bringing novel diagnostic tools to global markets. Grab Sources And More Here: VNRX Website. VNRX Presentation. ----- 5 Potential Catalysts Put (NYSE American: VNRX) Atop Our Watchlist This Week #1. An Analyst $2.50 Target May Be Signaling Triple-Digit Potential Upside. Last month, Zacks Small-Cap Research analyst, Steven Ralston, provided coverage on (NYSE American: VNRX) with a price forecast of $2.50. From Thursday's close, the target suggests a potential upside over 750%. Here's some highlights from the report: Outlook: Management’s primary operational goal for 2025 is (was) to secure multiple licensing agreements for human diagnostic applications. In September Volition entered into two such licensing agreements. The company’s 1st commercial order for Nu.Q Cancer assays was received in November. The key financial goal for 2025 is (was) to achieve cash neutrality on a full-year basis. In 3Q 2025, cash burn was reduced to 1.2Mn per month. Papers, posters, conference presentations, webinars etc. continue on a brisk pace. #2. Volition Announces Data to Support Use of Nu.Q® NETs in New Indication. VolitionRx Limited announced the publication of a new clinical study on MedRxiv highlighting the effectiveness of its Nu.Q® NETs assay in managing Hidradenitis Suppurativa (HS), a chronic disease affecting about 1% of the global population. The CE-marked assay, already approved across the EU, EEA, and U.K., offers a low-cost, accessible tool for identifying diseases associated with NETosis. Volition emphasized that Nu.Q® NETs supports personalized medicine and could transform both acute and chronic patient care, revealing a potentially lucrative $3.8Bn market opp. #3. VolitionRx Expands Global Reach Of Innovative Nu.Q® Vet Cancer Test. VolitionRx Limited announced two new centralized laboratory providers for its Nu.Q® Vet Cancer test—Midwest Veterinary Laboratory in the U.S. and Bioguard in Asia—broadening access to its pioneering canine cancer detection tool. Starting February 2026, the test will be available nationwide across the U.S. and through Bioguard’s ISO/IEC 17025-certified labs in Taiwan and China. This expansion strengthens Volition’s global presence, enabling earlier cancer detection during routine checkups and tapping into a growing market estimated at nearly $150Mn worldwide for canine cancer screening. #4. Breakthrough Feline Cancer Diagnostic Expands Market Potential For This Innovative Leader. VolitionRx has unveiled compelling clinical data showcasing the high accuracy of its Nu.Q® Vet Feline assay, achieving 100% specificity and detecting over 80% of feline lymphomas.  This advancement positions the company to launch the world’s first simple, affordable liquid biopsy test for cats, addressing a major gap in veterinary medicine. With a vast U.S. feline population, growing senior cat segment, and a rapidly expanding oncology market, this development reinforces VolitionRx’s technological leadership and commercial growth trajectory in animal health diagnostics. #5. VolitionRx Revolutionizes Cancer Detection Through Groundbreaking DNA Enrichment Technology. VolitionRx Limited unveiled a major advancement in liquid biopsy with its Capture-Seq™ method, achieving an unprecedented 180-fold (18,000%) enrichment of transcription factor-bound ultrashort DNA fragments. This innovation isolates cancer-related DNA from background blood DNA, enabling highly accurate, low-cost cancer detection. In initial trials, the method showed 100% sensitivity and specificity, even for early-stage cancers. The breakthrough could transform cancer diagnostics, expand Volition’s Nu.Q® portfolio, and tap into an estimated $23Bn annual market, positioning Volition as a leader in next-generation cancer testing. ----- Coverage is officially launched on (NYSE American: VNRX). Talk again shortly and be on the lookout for updates.  All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 01/30/2026 and ending on 01/30/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid twenty four thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (VNRX:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/vnrx-u0ych/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice